SLC5A2 and type 2 diabetes mellitus: While reductions in MI do not appear to be primarily involved in how SGLT2 inhibitors improve cardiovascular outcomes in people with T2DM, a plethora of preclinical studies have demonstrated that SGLT2 inhibitors decrease infarct size and alleviate ischemia/reperfusion injury.